Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12188/34404| Title: | Comparative analysis of global practices in the management of colchicine-resistant familial Mediterranean fever: a CliPS network analysis | Authors: | Haslak, Fatih Oner, Nimet Elhani, Inès Hinze, Tanja Mamutova, Anna Bourguiba, Rim Kasap Cuceoglu, Muserref Pateras, Konstantinos Aviel, Yonatan Butbul Delplanque, Marion Caorsi, Roberta Šestan, Mario Bénard, Stéphanie Ducharme Brunner, Jürgen El Moussaoui, Majdouline Kirijas, Meri Constantin, Tamas Arenas, Sonia Carriquí Khellaf, Ghalia Guliyeva, Vafa Assalia, Naiera Backes, Stefan Sozeri, Betul Hofer, Michaël Ayaz, Nuray Lachmann, Helen Wittkowski, Helmut Hentgen, Véronique |
Keywords: | amyloidosis Familial Mediterranean Fever Biological Therapy Interleukin 1 Receptor Antagonist Protein |
Issue Date: | 26-Sep-2025 | Publisher: | BMJ Publishing Group Ltd | Journal: | RMD open | Abstract: | Although colchicine is the mainstay of familial Mediterranean fever (FMF) treatment, 5-10% of patients are considered to have colchicine resistance (CR). However, there is no globally agreed CR definition or indications for biological disease-modifying anti-rheumatic drugs (bDMARDs). | URI: | http://hdl.handle.net/20.500.12188/34404 | DOI: | 10.1136/rmdopen-2025-006097 |
| Appears in Collections: | Faculty of Medicine: Journal Articles |
Show full item record
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.